In addition, intratumoral administration of ipilimumab in combination with interleukin-2 (IL-2) was investigated in a phase I trial in patients with unresectable stage III/IV melanoma, where a local response of injected lesions was observed in 67% patients, and an abscopal response in 89% [37]. The gene discussed is IL2; the disease is melanoma.